In 3127 adults with obesity without diabetes, once-daily oral orforglipron 6, 12 or 36 mg cut body weight by a mean 7.5%, 8.4% and 11.2% at 72 weeks vs 2.1% with placebo. Adverse-event discontinuation was 5.3–10.3% vs 2.7%, mainly gastrointestinal.
RCTn = 3,127
Wharton et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment